Clinical Trial Update: A Study to Investigate the Safety and Tolerability of TE-8105 in Overweight/Obese Participants Without Diabetes [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating TE-8105 for safety and tolerability in overweight/obese participants without diabetes has completed Phase 1 and Phase 2 stages.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• TE-8105

Snippet

Sponsor: Immunwork, Inc. | Conditions: Overweight and Obesity | Phase 1, Phase 2 | Status: COMPLETED